The EC and EMA have published a Q&A document concerning the legal consequences for marketing authorisation holders of centrally authorised medicines if the UK becomes a ‘third country’ after Brexit.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register. By continuing to use this site, you are consenting to our use of cookies.